Literature DB >> 24186318

Metronomic chemotherapy beyond misconceptions.

Eleftheria Hatzimichael1, Evangelos Briasoulis.   

Abstract

Keywords:  chemotherapy; metronomic therapy; multiple myeloma; relapsed refractory

Mesh：

Year:  2013        PMID： 24186318      PMCID： PMC3815190          DOI： 10.3324/haematol.2013.096917

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

Authors:  D Hanahan; G Bergers; E Bergsland
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 2.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

Review 3.  The anti-angiogenic basis of metronomic chemotherapy.

Authors:  Robert S Kerbel; Barton A Kamen
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

4.  The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.

Authors:  Amy E McKee; Ann T Farrell; Richard Pazdur; Janet Woodcock
Journal:  Oncologist       Date:  2010

Review 5.  Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy.

Authors:  Yuval Shaked; Robert S Kerbel
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

6.  Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer.

Authors:  Evangelos Briasoulis; Periklis Pappas; Christian Puozzo; Christos Tolis; George Fountzilas; Urania Dafni; Marios Marselos; Nicholas Pavlidis
Journal:  Clin Cancer Res       Date:  2009-10-06       Impact factor: 12.531

7.  Dose: a critical factor in cancer chemotherapy.

Authors:  E Frei; G P Canellos
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

8.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Authors:  S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

9.  Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.

Authors:  Xenofon Papanikolaou; Jackie Szymonifka; Adam Rosenthal; Christoph J Heuck; Alan Mitchell; Donald Johann; Jason Keller; Sarah Waheed; Saad Z Usmani; Frits Van Rhee; Clyde Bailey; Nathan Petty; Antje Hoering; John Crowley; Bart Barlogie
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

10.  Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.

Authors:  Evangelos Briasoulis; Gerasimos Aravantinos; George Kouvatseas; Periklis Pappas; Eirini Biziota; Ioannis Sainis; Thomas Makatsoris; Ioannis Varthalitis; Ioannis Xanthakis; Antonios Vassias; George Klouvas; Ioannis Boukovinas; George Fountzilas; Kostantinos N Syrigos; Haralambos Kalofonos; Epaminontas Samantas
Journal:  BMC Cancer       Date:  2013-05-29       Impact factor: 4.430
  10 in total
  1 in total

1.  Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells.

Authors:  Eirini Biziota; Evangelos Briasoulis; Leonidas Mavroeidis; Marios Marselos; Adrian L Harris; Periklis Pappas
Journal:  Anticancer Drugs       Date:  2016-03       Impact factor: 2.248
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.